Cannabis Stocks Pop on News of Jazz-GW Merger

Jazz Pharmaceuticals agreed to acquire GW Pharmaceuticals for $7.2 billion

By
Elana Dure
Elana Dure
Full Bio
Elana Duré is a markets writer for Investopedia. She covered shareholder activism as a reporter at Reorg and Activist Insight and her work has been published in The Washington Post, Chicago Tribune, and The Jerusalem Post.
Learn about our editorial policies
Published February 03, 2021
Cannabis plant
WIN-Initiative / Getty Images

Jazz Pharmaceuticals has agreed to acquire GW Pharmaceuticals, maker of the first epilepsy drug derived from marijuana, for $7.2 billion in cash and stock. 

The deal, which combines the two biopharmaceutical companies, signifies Jazz’s bet on the long-term prospects of cannabis-based therapies. 

Jazz will pay $200 in cash and $20 in stock per GW share. The transaction is expected to close in the second quarter.

Cannabis stocks jumped on the news, with shares in Sundial Growers and Tilray closing up 16% and 12%, respectively, on Wednesday.

cannabis stock prices

Cannabis investors are also optimistic after three Democratic Senators released a statement supporting the decriminalization of marijuana.

GW’s drug Epidiolex is used to treat rare forms of epilepsy and had global sales of $510 million within two years of its 2018 launch. The deal will strengthen Jazz’s neuroscience portfolio, said Jazz CEO and Chair Bruce Cozadd.

"We have a shared vision of developing and commercializing innovative medicines that address significant unmet needs in neuroscience and an approach of putting patients first,” GW CEO Justin Gover said. “Together, we will have an opportunity to reach and impact more patients through a broader portfolio of neuroscience-focused therapies than ever before."

Shares in GW closed upy 44.5% on the news Wednesday, while shares in Jazz closed down nearly 4%.

Article Sources
Investopedia requires writers to use primary sources to support their work. These include white papers, government data, original reporting, and interviews with industry experts. We also reference original research from other reputable publishers where appropriate. You can learn more about the standards we follow in producing accurate, unbiased content in our editorial policy.

  1. Jazz Pharmaceuticals. "Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader."

  2. The Wall Street Journal. "Jazz Pharmaceuticals to Buy Cannabis-Based Drugmaker GW Pharma for $6.7 Billion."

  3. Marijuana Moment. "Democratic Senate Leaders Announce Steps To Federally Legalize Marijuana In 2021."

Take the Next Step to Invest
×
The offers that appear in this table are from partnerships from which Investopedia receives compensation. This compensation may impact how and where listings appear. Investopedia does not include all offers available in the marketplace.
Service
Name
Description